ClinicaliQ Trial Snapshot
- Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma — Active Not Recruiting • Phase II • NCT05004064.
- Acalabrutinib plus rituximab showed promise as a gentler first-line treatment option for elderly or frail patients with mantle cell lymphoma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma. Conditions: Mantle Cell Lymphoma Interventions: Acalabrutinib, Rituximab Lead Sponsor: University College, London Planned Enrollment: 48 participants